MADOPAR (Madopar).

     Madopar a combined product containing L-Dov for the same actions with karbidopoy inhibitor L-Dov decomposition of the blood and peripheral organs - benserazidom.

     Benserazid or serazid, is the N - (DL- Pam) - N - (2, 3, 4-trioksibenzil) - Hydrazine (hydrochloride).

     Madopar issued capsules containing 50 mg levodopa 12, 5 mg benserazida (Madopar 62, 5); Levodopa 100 mg and 25 mg benserazida (madopar-125) and 200 mg to 50 mg levodopa benserazida (madopar-250).

     Indications for use are the same as for Nacoma.

     Started treatment with admission to 1-125 madopara capsule 3 times a day for one week. Then, at intervals of one week, increasing the dose of 1 capsule to achieve an optimal effect. The therapeutic dose is usually 4 to 8 capsules (10 capsules rarely madopara-125) in the day (3 to 4 admission). If a daily dose greater than 5 capsules madopara-125, can be applied madopar-250 from the account.

     The average dose for maintenance therapy is usually one capsule madopara-250 3 times a day.

     Capsule madopara-62, 5 to better regulate dosage if necessary reduction of dose or dose-125 madopara 2 admission.

     Possible side effects, precautions and contraindications such as when applying Nacoma.

Materials allowed to copy only with the active hyperlink to the handbook of medicines